Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review

Christopher G Fawsitt, Elaine Gallagher, Alka Singh, Hannah Baker, Edward Kayongo, Howard Thom and Noman Paracha ()
Additional contact information
Christopher G Fawsitt: Clifton Insight
Elaine Gallagher: Bayer Pharmaceuticals AG
Alka Singh: Mtech Access
Hannah Baker: Mtech Access
Edward Kayongo: Clifton Insight
Howard Thom: Clifton Insight
Noman Paracha: Bayer Pharmaceuticals AG

PharmacoEconomics, 2025, vol. 43, issue 11, No 6, 1323-1338

Abstract: Abstract Background and Objectives Metastatic castration-sensitive prostate cancer (mCSPC) imposes a significant economic burden and necessitates more cost-effective treatment strategies. The variability among the components of published economic evaluation models leads to methodological inconsistencies, underscoring the need for an optimal framework to minimise unwarranted structural variation. This paper reviews existing economic evaluations, establishes a comprehensive framework and aims to support future economic evaluations and decision-making in mCSPC. Methods A systematic literature review (SLR) was conducted to identify relevant economic evaluations in mCSPC. Health technology assessments (HTAs) by the National Institute for Health and Care Excellence, and Canada’s Drug Agency were reviewed to gather insights on critiques and limitations. On the basis of these findings, a comprehensive cost-effectiveness modelling framework was established. Furthermore, two additional SLRs were conducted to identify cost and resource utilisation inputs, as well as health state utility scores derived from published studies and HTA assessments. Results Markov models and partitioned survival models (PSMs) were commonly reported in literature and published HTA evaluations. Despite the strong precedence of PSMs, we propose an optimal framework for mCSPC utilising a semi-Markov structure. This approach offers increased flexibility, allowing transition rates from progressed states to depend on time since progression occurred. We also present key sources of cost and utility data identified in the SLR. Discussion This work aligns with methodologies recommended by the Innovative Medicine Initiative (IMI) PIONEER external group and published studies. The optimal framework, including healthcare resource utilisation and utility data, consolidates existing modelling precedents in mCSPC and will assist the cost-effectiveness assessment of treatments for this condition.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-025-01532-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:11:d:10.1007_s40273-025-01532-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-025-01532-w

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().